Covered recipient · General Payments record
AMY KATHRYN KRIE
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$230,927.60
216 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $179,315.00 | 43 |
| Travel and Lodging | $29,966.33 | 115 |
| Consulting Fee | $19,383.75 | 13 |
| Food and Beverage | $2,219.27 | 44 |
| Education | $43.25 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $102,050.17 | 90 |
| Daiichi Sankyo Inc. | $60,921.63 | 54 |
| Gilead Sciences, Inc. | $38,752.17 | 41 |
| Stemline Therapeutics Inc. | $29,203.63 | 31 |
Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AMY KATHRYN KRIE
NPI 1083648075 · CMS profile ID 507995
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
MINNEAPOLIS, MN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1083648075?year=2025&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AMY KATHRYN KRIE, NPI 1083648075, CMS profile ID 507995. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083648075?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). AMY KATHRYN KRIE, NPI 1083648075, CMS profile ID 507995. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083648075?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- AMY KATHRYN KRIE, NPI 1083648075, CMS profile ID 507995, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–216 of 216 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1083648075?year=2025&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
216 matching records · $230,927.60 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–216 of 216.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $40.09 | 01/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234372981 | CMS |
| Gilead Sciences, Inc. | $27.92 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234452056 | CMS |
| Gilead Sciences, Inc. | $8.78 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234589704 | CMS |
| Gilead Sciences, Inc. | $5.45 | 01/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234601200 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,360.00 | 01/28/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207200780 | CMS |
| Gilead Sciences, Inc. | $199.00 | 01/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234369898 | CMS |
| Gilead Sciences, Inc. | $20.75 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234520661 | CMS |
| Gilead Sciences, Inc. | $17.29 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234555333 | CMS |
| Gilead Sciences, Inc. | $15.12 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234571356 | CMS |
| Gilead Sciences, Inc. | $13.10 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234581060 | CMS |
| Gilead Sciences, Inc. | $5.45 | 01/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234601198 | CMS |
| AstraZeneca Pharmaceuticals LP | $406.94 | 01/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206826355 | CMS |
| AstraZeneca Pharmaceuticals LP | $123.63 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206864778 | CMS |
| AstraZeneca Pharmaceuticals LP | $209.81 | 01/22/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207279903 | CMS |
| AstraZeneca Pharmaceuticals LP | $670.00 | 01/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206680670 | CMS |
| Daiichi Sankyo Inc. | $416.25 | 01/08/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197097217 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $670,613.85 | 30 |
| PY2024 | Recipient | $2,310.00 | 1 |
| PY2024 | Principal investigator | $208,067.30 | 10 |
| PY2023 | Recipient | $1,989.22 | 1 |
| PY2023 | Principal investigator | $72,192.18 | 21 |
| PY2022 | Principal investigator | $70,957.45 | 17 |
| PY2021 | Principal investigator | $366,141.35 | 25 |
| PY2020 | Principal investigator | $54,009.11 | 22 |
| PY2019 | Principal investigator | $116,865.82 | 27 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
30 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $175.09 | 12/31/2025 | Covered Recipient Teaching Hospital Abbott Northwestern Hospital | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - KEYNOTE-355 | No dispute reported | 06/30/2026 | 1232926021 |
| Principal investigator 1 | PFIZER INC. | $8,916.87 | 12/27/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228749157 |
| Principal investigator 1 | PFIZER INC. | $5,657.31 | 12/13/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228743757 |
| Principal investigator 1 | PFIZER INC. | $30.00 | 12/08/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712410 |
| Principal investigator 1 | PFIZER INC. | $21,256.38 | 11/26/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228728201 |
| Principal investigator 1 | PFIZER INC. | $13,348.53 | 11/05/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228729426 |
| Principal investigator 1 | PFIZER INC. | $6,960.44 | 10/31/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228729933 |
| Principal investigator 1 | PFIZER INC. | $30.00 | 10/27/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712272 |
| Principal investigator 1 | PFIZER INC. | $173.75 | 10/09/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228741844 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 09/24/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712214 |
| Principal investigator 1 | PFIZER INC. | $30.00 | 09/24/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712274 |
| Principal investigator 1 | PFIZER INC. | $8,902.97 | 09/24/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228770934 |
| Principal investigator 1 | PFIZER INC. | $3,544.85 | 09/09/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228771244 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $34,811.71 | 08/31/2025 | Covered Recipient Teaching Hospital Abbott Northwestern Hospital | A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr | No dispute reported | 06/30/2026 | 1232922980 |
| Principal investigator 1 | PFIZER INC. | $5,004.01 | 08/29/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228766718 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 08/15/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712348 |
| Principal investigator 1 | PFIZER INC. | $6,258.83 | 07/31/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228763225 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 07/25/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712212 |
| Principal investigator 1 | PFIZER INC. | $28,830.00 | 07/16/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228781630 |
| Principal investigator 1 | PFIZER INC. | $16,330.08 | 07/01/2025 | Covered Recipient Teaching Hospital Mercy Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228712412 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 06/23/2025 | Non-covered Recipient Entity Allina Health Cancer Institute | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228768550 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 06/23/2025 | Non-covered Recipient Entity Allina Health Cancer Institute | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228771472 |
| Principal investigator 1 | PFIZER INC. | $17,200.00 | 03/07/2025 | Covered Recipient Teaching Hospital Mercy Hospital | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228790008 |
| Principal investigator 1 | PFIZER INC. | $5,500.00 | 02/18/2025 | Covered Recipient Teaching Hospital Mercy Hospital | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1228787702 |
| Principal investigator 1 | PFIZER INC. | $5,500.00 | 02/18/2025 | Covered Recipient Teaching Hospital Mercy Hospital | A SINGLE ARM OPEN LABEL PHASE 2 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER | No dispute reported | 06/30/2026 | 1228789187 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 02/03/2025 | Covered Recipient Teaching Hospital Mercy Hospital | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB | No dispute reported | 06/30/2026 | 1228781527 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 02/03/2025 | Covered Recipient Teaching Hospital Mercy Hospital | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB | No dispute reported | 06/30/2026 | 1228784133 |
| Principal investigator 1 | PFIZER INC. | $3,500.00 | 02/03/2025 | Covered Recipient Teaching Hospital Mercy Hospital | SINGLE ARM OPEN LABEL PHASE 1B2 STUDY OF SGNLIV1A IN COMBINATION WITH PEMBROLIZUMAB FOR FIRSTLINE TREATMENT OF PATIENTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC TRIPLENEGATIVE BREAST CANCER | No dispute reported | 06/30/2026 | 1228792644 |
| Principal investigator 1 | Eli Lilly and Company | $5,387.33 | 01/09/2025 | Covered Recipient Teaching Hospital UNITED HOSPITAL | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187873563 |
| Principal investigator 1 | Eli Lilly and Company | $338,612.00 | 01/07/2025 | Covered Recipient Teaching Hospital UNITED HOSPITAL | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187873561 |